[144] Nektar Therapeutics SEC Filing
Nektar Therapeutics (NKTR) filed a Form 144 notifying the proposed sale of 1,573 common shares acquired on 08/15/2025 through restricted stock vesting. The filer lists an aggregate market value of $41,826.23 for those shares and reports approximately 19,018,573 shares outstanding. The proposed sale date is 08/19/2025 on NASDAQ, and the securities were recorded as compensation. The filing also discloses that Howard Robin sold 23,208 common shares on 05/19/2025 for gross proceeds of $15,579.54. The notice includes the standard representation that the signer does not possess undisclosed material adverse information.
Nektar Therapeutics (NKTR) ha presentato un modulo 144 per comunicare la proposta di vendita di 1.573 azioni ordinarie acquisite il 15/08/2025 tramite vesting di azioni soggette a restrizioni. Il dichiarante indica un valore di mercato complessivo di $41.826,23 per tali azioni e segnala circa 19.018.573 azioni in circolazione. La vendita 猫 prevista per il 19/08/2025 sul NASDAQ, e i titoli sono stati registrati come retribuzione. La comunicazione riferisce inoltre che Howard Robin ha venduto 23.208 azioni ordinarie il 19/05/2025 per proventi lordi pari a $15.579,54. L'avviso include la consueta dichiarazione secondo cui il firmatario non 猫 in possesso di informazioni riservate materialmente sfavorevoli non divulgate.
Nektar Therapeutics (NKTR) present贸 un Formulario 144 notificando la propuesta de venta de 1.573 acciones comunes adquiridas el 15/08/2025 mediante la consolidaci贸n de acciones restringidas. El declarante indica un valor de mercado agregado de $41.826,23 por esas acciones y reporta aproximadamente 19.018.573 acciones en circulaci贸n. La venta propuesta est谩 prevista para el 19/08/2025 en el NASDAQ, y los t铆tulos fueron registrados como compensaci贸n. La presentaci贸n tambi茅n revela que Howard Robin 惫别苍诲颈贸 23.208 acciones comunes el 19/05/2025 por ingresos brutos de $15.579,54. El aviso incluye la representaci贸n est谩ndar de que quien firma no posee informaci贸n adversa material no divulgada.
Nektar Therapeutics (NKTR)电� 鞝滍暅欤检嫕 氩犾姢韺�鞚� 韱淀暣 2025-08-15鞐� 旆摑頃� 1,573 氤错喌欤� 毵る弰毳� 韱奠頃樀鐢 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖鞛惖鐢 頃措嫻 欤检嫕鞚� 齑� 鞁滉皜毳� $41,826.23搿� 旮办灛頄堨溂氅�, 鞙犿喌 欤检嫕靾樀鐢 鞎� 19,018,573欤茧澕瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌晥霅� 毵る弰鞚检潃 2025-08-19搿� NASDAQ鞐愳劀 鞚措歆� 鞓堨爼鞚措┌, 頃措嫻 歃濌秾鞚� 氤挫儊鞙茧 旮半霅橃棃鞀惦媹雼�. 靹滊鞐惖鐢 霕愴暅 Howard Robin鞚� 2025-05-19鞐� 23,208 氤错喌欤茧ゼ 毵る弰頃� 齑� $15,579.54毳� 鞏混棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓿奠鞐惖鐢 靹滊獏鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟电� 響滌 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Nektar Therapeutics (NKTR) a d茅pos茅 un formulaire 144 indiquant la vente propos茅e de 1 573 actions ordinaires acquises le 15/08/2025 par vesting d'actions restreintes. Le d茅clarant indique une valeur de march茅 agr茅g茅e de 41 826,23 $ pour ces actions et fait 茅tat d'environ 19 018 573 actions en circulation. La date de vente propos茅e est le 19/08/2025 sur le NASDAQ, et les titres ont 茅t茅 enregistr茅s comme r茅mun茅ration. Le d茅p么t r茅v猫le 茅galement que Howard Robin a vendu 23 208 actions ordinaires le 19/05/2025 pour des produits bruts de 15 579,54 $. L'avis comprend la d茅claration standard selon laquelle le signataire ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Nektar Therapeutics (NKTR) reichte ein Formular 144 ein und meldete den beabsichtigten Verkauf von 1.573 Stammaktien, die am 15.08.2025 durch Restricted-Stock-Vesting erworben wurden. Der Einreicher nennt einen aggregierten Marktwert von $41.826,23 f眉r diese Aktien und gibt rund 19.018.573 ausstehende Aktien an. Der vorgeschlagene Verkaufstermin ist der 19.08.2025 an der NASDAQ, und die Wertpapiere wurden als Verg眉tung verbucht. Die Einreichung offenbart au脽erdem, dass Howard Robin am 19.05.2025 23.208 Stammaktien ver盲u脽erte und dabei Bruttoerl枚se von $15.579,54 erzielte. Die Mitteilung enth盲lt die 眉bliche Erkl盲rung, dass der Unterzeichner keine nicht offengelegten, wesentlich nachteiligen Informationen besitzt.
- Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale and acquisition method, supporting regulatory transparency
- Acquisition via compensation: The 1,573 shares were acquired through restricted stock vesting, a common, non-market-price-based grant
- Insider sale: Howard Robin sold 23,208 shares on 05/19/2025, indicating recent insider liquidity
- Small aggregated market value relative to potential investor concern: The proposed sale value is $41,826.23, which may draw attention despite being modest
Insights
TL;DR: Insider issued and proposing sale are routine compensation-related and small relative to total shares outstanding.
The filing reports a restricted stock vesting of 1,573 shares converted to a proposed sale on 08/19/2025 with an aggregate market value of $41,826.23. Such Form 144 notices are procedural when insiders sell shares received as compensation; they provide transparency about timing and planned disposition. The prior sale by Howard Robin of 23,208 shares on 05/19/2025 is disclosed, showing recent insider liquidity. Based solely on the filing, these transactions are disclosed but do not, by themselves, indicate operational changes at the issuer.
TL;DR: Filing documents compliance with Rule 144 and includes required insider certification; no undisclosed material facts asserted.
The notice includes the required certification that the seller is unaware of undisclosed material adverse information and documents the nature of acquisition as compensation. The combination of vesting-triggered shares and a recent separate sale by an individual insider is consistent with routine executive compensation and liquidity events. From a governance standpoint, timely disclosure via Form 144 meets regulatory transparency expectations.
Nektar Therapeutics (NKTR) ha presentato un modulo 144 per comunicare la proposta di vendita di 1.573 azioni ordinarie acquisite il 15/08/2025 tramite vesting di azioni soggette a restrizioni. Il dichiarante indica un valore di mercato complessivo di $41.826,23 per tali azioni e segnala circa 19.018.573 azioni in circolazione. La vendita 猫 prevista per il 19/08/2025 sul NASDAQ, e i titoli sono stati registrati come retribuzione. La comunicazione riferisce inoltre che Howard Robin ha venduto 23.208 azioni ordinarie il 19/05/2025 per proventi lordi pari a $15.579,54. L'avviso include la consueta dichiarazione secondo cui il firmatario non 猫 in possesso di informazioni riservate materialmente sfavorevoli non divulgate.
Nektar Therapeutics (NKTR) present贸 un Formulario 144 notificando la propuesta de venta de 1.573 acciones comunes adquiridas el 15/08/2025 mediante la consolidaci贸n de acciones restringidas. El declarante indica un valor de mercado agregado de $41.826,23 por esas acciones y reporta aproximadamente 19.018.573 acciones en circulaci贸n. La venta propuesta est谩 prevista para el 19/08/2025 en el NASDAQ, y los t铆tulos fueron registrados como compensaci贸n. La presentaci贸n tambi茅n revela que Howard Robin 惫别苍诲颈贸 23.208 acciones comunes el 19/05/2025 por ingresos brutos de $15.579,54. El aviso incluye la representaci贸n est谩ndar de que quien firma no posee informaci贸n adversa material no divulgada.
Nektar Therapeutics (NKTR)电� 鞝滍暅欤检嫕 氩犾姢韺�鞚� 韱淀暣 2025-08-15鞐� 旆摑頃� 1,573 氤错喌欤� 毵る弰毳� 韱奠頃樀鐢 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖鞛惖鐢 頃措嫻 欤检嫕鞚� 齑� 鞁滉皜毳� $41,826.23搿� 旮办灛頄堨溂氅�, 鞙犿喌 欤检嫕靾樀鐢 鞎� 19,018,573欤茧澕瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌晥霅� 毵る弰鞚检潃 2025-08-19搿� NASDAQ鞐愳劀 鞚措歆� 鞓堨爼鞚措┌, 頃措嫻 歃濌秾鞚� 氤挫儊鞙茧 旮半霅橃棃鞀惦媹雼�. 靹滊鞐惖鐢 霕愴暅 Howard Robin鞚� 2025-05-19鞐� 23,208 氤错喌欤茧ゼ 毵る弰頃� 齑� $15,579.54毳� 鞏混棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓿奠鞐惖鐢 靹滊獏鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟电� 響滌 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Nektar Therapeutics (NKTR) a d茅pos茅 un formulaire 144 indiquant la vente propos茅e de 1 573 actions ordinaires acquises le 15/08/2025 par vesting d'actions restreintes. Le d茅clarant indique une valeur de march茅 agr茅g茅e de 41 826,23 $ pour ces actions et fait 茅tat d'environ 19 018 573 actions en circulation. La date de vente propos茅e est le 19/08/2025 sur le NASDAQ, et les titres ont 茅t茅 enregistr茅s comme r茅mun茅ration. Le d茅p么t r茅v猫le 茅galement que Howard Robin a vendu 23 208 actions ordinaires le 19/05/2025 pour des produits bruts de 15 579,54 $. L'avis comprend la d茅claration standard selon laquelle le signataire ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Nektar Therapeutics (NKTR) reichte ein Formular 144 ein und meldete den beabsichtigten Verkauf von 1.573 Stammaktien, die am 15.08.2025 durch Restricted-Stock-Vesting erworben wurden. Der Einreicher nennt einen aggregierten Marktwert von $41.826,23 f眉r diese Aktien und gibt rund 19.018.573 ausstehende Aktien an. Der vorgeschlagene Verkaufstermin ist der 19.08.2025 an der NASDAQ, und die Wertpapiere wurden als Verg眉tung verbucht. Die Einreichung offenbart au脽erdem, dass Howard Robin am 19.05.2025 23.208 Stammaktien ver盲u脽erte und dabei Bruttoerl枚se von $15.579,54 erzielte. Die Mitteilung enth盲lt die 眉bliche Erkl盲rung, dass der Unterzeichner keine nicht offengelegten, wesentlich nachteiligen Informationen besitzt.
FAQ
What does the Form 144 filed by NKTR disclose?
How many shares does Nektar report outstanding in the filing?
Did any insider sell NKTR shares recently according to this filing?
How were the 1,573 shares acquired?
When is the proposed sale date and on which exchange will it occur?
